Biovista Inc., of Charlottesville, Va., said its European Union affiliate has been awarded a $500,000 grant for R&D in personalized medicine as part of the "p-medicine" project, a four-year effort under the European Community's 7th Framework Programme. Biovista said it will use its Clinical Outcomes Search Space platform multidimensional profiling capabilities to identify treatments that reflect patients' individual pathophysiological characteristics.